Bitcoin Roars Past $70,000 as Yields Sink, Trump Sparks Optimism
The doses include 20,000 for a Phase 3 trial and 50,000 for front-line workers as officials race to curb the Bundibugyo strain.
- Congo will receive 70,000 doses of the Ervebo Ebola vaccine, with 50,000 doses mainly to protect frontline and healthcare workers and 20,000 doses for a Phase III clinical trial assessing the vaccine's effectiveness against the Bundibugyo virus strain.
- Ervebo is licensed against the Ebola virus's Zaire strain but not specifically approved for the Bundibugyo strain, though early studies suggest it might offer some protection.
- Since the outbreak began, DR Congo has reported over 5,000 cases and more than 2,300 deaths, making it the deadliest Ebola outbreak in the country.
- The clinical trial with 20,000 doses aims to assess Ervebo's effectiveness against the Bundibugyo strain as recommended by WHO vaccine experts.
59 Articles
59 Articles
The vaccine is registered against the Zaire strain of the virus, but not against the current Bundibugyo strain in the country, but it could offer some protection.
News quickly and reliably.
In the face of the Ebola epidemic in the Democratic Republic of the Congo (DRC), the WHO announced on Thursday the availability of 70,000 doses of Ervebo vaccine, registered against the Zaire strain of the virus but not against the Bundibugyo strain currently in the country. ...
Ebola Epidemic 70,000 Doses of Ervebo Vaccine Made Available to the Democratic Republic of the Congo
In the face of the Ebola epidemic in the Democratic Republic of the Congo (DRC), WHO announced on Thursday the availability of 70,000 doses of Ervebo vaccine, registered against the Zaire strain of the virus but not against the Bundibugyo strain currently in the country.
Coverage Details
Bias Distribution
- 47% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
